The adjuvant use of osimertinib was FDA approved on 18 December 2020 and extended to stage IB-IIIA NSCLC (non-squamous) patients whose tumors harbored EGFR exon 19 deletions or exon 21 L858R mutations [215]. Here, EGFR is linked to non-small cell lung carcinoma.